Guidelines for Using Lamotrigine and Valproate Together
The combination of lamotrigine and valproate requires significant dose adjustments due to their bidirectional pharmacokinetic interaction, with valproate increasing lamotrigine levels by 165% and lamotrigine decreasing valproate levels by approximately 25%. 1
Pharmacokinetic Interaction
Effect of Valproate on Lamotrigine
- Valproate markedly increases lamotrigine's half-life from 26 to 70 hours (165% increase) 1
- This occurs through inhibition of lamotrigine's glucuronidation 2
- Consequence: Lamotrigine doses must be substantially reduced when used with valproate
Effect of Lamotrigine on Valproate
- Lamotrigine decreases valproate plasma concentrations by approximately 25% 2
- Increases valproate oral clearance from 7.2 to 9.0 ml/hr/kg 2
- Importantly, lamotrigine does not increase formation of hepatotoxic valproate metabolites 2
Dosing Recommendations
Starting Lamotrigine with Existing Valproate
- Use much lower lamotrigine starting doses (typically 25 mg every other day)
- Titrate more slowly than usual (over several weeks)
- Target a lower maintenance dose (typically 50-200 mg/day) compared to lamotrigine monotherapy 1, 3
Starting Valproate with Existing Lamotrigine
- Reduce lamotrigine dose by 50% when adding valproate
- Monitor lamotrigine levels and adjust as needed
- Be prepared for potential toxicity as lamotrigine levels rise 1
Converting from Valproate to Lamotrigine
A four-step algorithm has been validated for this transition 3:
- Add lamotrigine at low dose and slowly titrate to 200 mg daily while maintaining valproate
- Begin gradual valproate withdrawal over 6 weeks
- Increase lamotrigine to 500 mg daily as valproate is discontinued
- Monitor lamotrigine levels throughout to maintain stable concentrations
Safety Considerations
Rash Risk
- Serious skin reactions (Stevens-Johnson Syndrome and toxic epidermal necrolysis) have been reported with concomitant use 1
- Starting with very low lamotrigine doses when combined with valproate reduces rash risk to levels comparable to other combinations 4
- Rash incidence is approximately 13-14% but discontinuation is required in only 7-9% of cases 4
Other Adverse Effects
- Monitor for:
- Early effects: Fatigue (12%), gastrointestinal symptoms (9%), dizziness, headache, insomnia (3% each) 4
- Late-onset effects: Ataxia, vertigo, headache, and rare movement disorders like tics may occur 9 months to 2 years after final dose adjustment 5
- These late effects typically resolve with small dose reductions 5
Monitoring Recommendations
- Check lamotrigine and valproate levels at baseline and after each significant dose change
- Monitor more frequently during the first 8 weeks of combination therapy
- Assess for clinical signs of toxicity at each visit (ataxia, dizziness, diplopia, headache)
- Perform periodic liver function tests
- Evaluate for skin reactions, especially during the first 8 weeks of treatment
Clinical Applications
This combination is particularly useful in:
- Bipolar disorder where valproate alone is insufficient 6
- Epilepsy patients with mixed seizure types 6
- Cases where monotherapy with either agent provides partial but incomplete seizure control
Pitfalls to Avoid
- Starting lamotrigine at standard doses when adding to valproate (will lead to toxicity)
- Failing to reduce lamotrigine dose when adding valproate to an existing regimen
- Overlooking late-onset adverse effects that can occur months or years after stable dosing
- Discontinuing the combination prematurely due to minor side effects that could be managed with dose adjustments
- Abrupt withdrawal of either medication (lamotrigine should be tapered over at least 4 weeks)
By following these guidelines, the lamotrigine-valproate combination can be used effectively and safely in appropriate patients.